Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn
Torrent Pharmaceuticals, headquartered in Gujerat, India, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals…
Ophthalmology
-
-
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency…
-
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the…
-
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) in single-dose prefilled syringe form for three retinal conditions that…
-
Formosa and Medvisis agree on post-operative eye pain therapy
Formosa Pharmaceuticals in Taiwan has signed an exclusive licensing agreement with Medvisis Switzerland to commercialise clobetasol propionate ophthalmic suspension, 0.05%…
-
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has…
-
FDA delays priority review of Neurotech’s eye cell therapy implant
Neurotech Pharmaceuticals’ eye cell therapy implant has faced a setback as the US Food and Drug Administration (FDA) has extended…
-
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients
On October 20, at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, IL, US,…
-
Glaukos eyes FDA approval for ocular therapy after Phase III win
Glaukos plans to file for US approval of its iLink corneal cross-linking therapy Epioxa (Epi-on) for treating keratoconus after the…
-
Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy
Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for…
